Cortexyme Says There's A Caveat In Its Missed Alzheimer's Test — But Shares Crash

Cortexyme Says There's A Caveat In Its Missed Alzheimer's Test — But Shares Crash

Cortexyme executives lauded the study that helped narrow the patient pool for its Alzheimer's drug, but CRTX stock hit a record low on Wednesday.